Navigation Links
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics

New Rochelle, NY, October 3, 2008Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). The payoff for successful molecular diagnostic products can be significant as Kalorama Information predicts that this market currently exceeds $3.2 billion worldwide and will reach $5.4 billion in four years, according to an article in the October 1 issue of GEN.

"Molecular diagnostic products are based on cutting-edge research in two of the most promising biotechnologies, genomics and proteomics. These novel tests also utilize sophisticated analytical techniques such as microarrays and mass spectrometry," notes John Sterling, Editor-in-Chief of GEN. "Molecular diagnostics are particularly applicable to the early detection of cancer."

Affymetrix and Illumina have both created array-based products that enable high-speed analysis of DNA, RNA, and proteins as tools for disease research, drug development, and molecular tests. These gene-sequencing tools are being applied at an earlier stage.

Genetic tests can optimize drug therapy, and companion diagnostics are being touted as a method to better define a patient's need or predict clinical outcome from a specific drug. The FDA recently approved a HER-2 test from Invitrogen called Spot-Light that can be used to identify breast cancer patients who are candidates for treatment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of Erbitux for metastatic colorectal cancer.

Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostics and biopharmaceuticals and is well positioned for the future with products in oncology and infectious disease. Its genetic tests include CYP450 for drug metabolism studies and HER-2 for use with tamoxifen therapy.

Other companies covered in the GEN article include Myriad Genetics, Genomic Health, Genoptix, Luminex, Abbott Labs, Aureon, Autogenomics, Nanosphere, Navigenics, Osmetech, and Perlegen Sciences.


Contact: John Sterling
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology technology :

1. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
2. Genetically Modified Canola Plantings Reach 90 Percent in Canada
3. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
4. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
5. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
8. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
9. deCODE genetics Announces Second Quarter 2008 Financial Results
10. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
11. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
Breaking Biology Technology:
(Date:11/20/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet, ... interviewed on The RedChip Money Report television ... Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, and ... ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):